Bladder Cancer: Page 2

Guardant highlights data on multicancer test at AACR 2022
By LabPulse.com staff writers
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
2017 09 14 23 05 1167 Cancer Cell 400
ASCO study touts data from bladder cancer clinical trial
By Leah Sherwood
The identification of a biomarker for predicting bladder cancer survival comes out the secondary part of the S1314 clinical trial, which measured long-term survival data in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery.
February 13, 2022
2019 05 09 16 46 9205 Bladder Cancer 400
AnchorDx bladder cancer test gets FDA 'breakthrough' designation
By LabPulse.com staff writers
The test, UriFind, received the first breakthrough designation granted to a company in China for a liquid biopsy test for bladder cancer detection. The test is as accurate as a cystoscopy and significantly better than exfoliative cytology and fluorescence in situ hybridization (FISH) in detecting early and nonmuscle-invasive bladder cancer, according to the company.
July 20, 2021
2019 05 09 16 46 9205 Bladder Cancer 400
Natera and BGI launch new assay in China
By LabPulse.com staff writers
The Signatera assay was tested in studies in nonsmall cell lung, bladder, breast, and colorectal cancers and identifies MRD up to two years earlier than standard imaging, the companies said in a release.
June 23, 2021
2019 08 12 20 23 3708 Lab Blood Centrifuge 400
Nucleix showcases Bladder EpiCheck at EAU 2020
By LabPulse.com staff writers
The first presentation, titled "Feasibility of the EpiCheck test in upper tract tumor: Interim analysis of a prospective trial," described the evaluation of 47 patients who had undergone ureteroscopy for primary or recurrent upper tract urothelial cancer (UTUC) since June 1, 2018. Each patient had cytology and Bladder EpiCheck tests performed on voided urine and selective urine samples. Researchers found that 46% of patients were positive for UTUC as confirmed by endoscopic biopsy, half of which were high-grade. The interim analysis reported a significantly higher overall sensitivity of Bladder EpiCheck compared with cytology in voided urine (75% versus 39%). Bladder EpiCheck also displayed a higher sensitivity than cytology in high-grade UTUC (89% versus 64%) and a negative predictive value (NPV) of 95% versus 88% in voided urine.
July 19, 2020
2019 05 09 16 46 9205 Bladder Cancer 400
Nucleix highlights data for urine test in detecting bladder cancer
By LabPulse.com staff writers
In a study of 374 patients at Agostino Gemelli University Hospital in Rome, Italy, the firm's methylation-based assay outperformed cytology alone and yielded high sensitivity, specificity, and negative predictive value, Nucleix said. The findings support the use of Bladder EpiCheck to detect recurrence of NMIBC in patients who have undergone instillations, according to the vendor.
June 29, 2020
2019 05 09 16 46 9205 Bladder Cancer 400
Google reports pathology AI helps predict survival in cancer patients
By Emily Hayes
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
2020 06 16 21 12 7935 Artificial Intelligence Ai Hand 400
KDx bladder cancer urine test gets breakthrough designation
By LabPulse.com staff writers
The test screens for keratin 17, a protein biomarker for urothelial cancer. It was invented by KDx co-founder Nam Kim, PhD, with research groundwork contributed by Dr. Kenneth Shroyer, PhD, chair of pathology at Stony Brook Medicine. KDx is positioning it as a noninvasive alternative to cystoscopy, which involves the insertion of a hollow tube with a lens through the urethra into the bladder.
January 9, 2020
2019 05 02 19 24 6251 Lab Urine Test 400
LabCorp launches Qiagen's FGFR test for bladder cancer
By LabPulse.com staff writers
The FGFR Rotor-Gene Q (RGQ) reverse transcription polymerase chain reaction (RT-PCR) kit is the first product introduced through LabCorp's participation with Qiagen in a lab readiness program aimed at making new companion diagnostics available for drugs soon after approval by the U.S. Food and Drug Administration (FDA).
May 9, 2019
2019 05 10 17 42 3167 Lab Doctors Dna 400
Natera touts liquid biopsy in bladder cancer
By LabPulse.com staff writers
Researchers evaluated use of the test in 68 patients with muscle invasive bladder cancer who received neoadjuvant chemotherapy before cystectomy at Aarhus University in Denmark. They examined a total of 656 blood samples taken at the time of diagnosis, during chemotherapy treatment, before cystectomy, and in post-treatment monitoring.
May 8, 2019
2019 05 09 16 46 9205 Bladder Cancer 400
Previous Page
Page 2 of 2